Flu Vaccines Reduced Severe Disease and Mortality
A new systematic review confirms the efficacy of influenza vaccines in preventing hospitalization and death.
Updated on Sept. 28, 2026 in Asthma
Live Poll
Do you trust influenza vaccine recommendations issued without the guidance of federal advisory committees?
A comprehensive systematic review of 69 studies has confirmed that influenza vaccination significantly reduces the risk of severe disease and mortality. The analysis supports current immunization efforts ahead of the 2026-2027 respiratory season.
Why it matters
Understanding the efficacy of various influenza vaccines is critical for guiding public health recommendations and ensuring the protection of vulnerable populations. These findings provide evidence-based support for seasonal vaccination strategies.
A systematic review of 69 studies demonstrated high vaccine efficacy, including 43.6% relative effectiveness for high-dose shots and 80% prevention of pediatric deaths. The mRNA-1010 vaccine was also analyzed, showing 6.4% Grade 3 reaction rates compared to 1.0% for standard doses.
The players
University of Minnesota
This academic institution served as the research lead for the systematic review of influenza vaccine data.
US Department of Health and Human Services
This federal agency oversees national health policy and recently dismissed the members of the Advisory Committee on Immunization Practices.
The details
Researchers analyzed 21 randomized trials and dozens of observational studies to assess vaccine performance, finding consistent reductions in hospitalization risk. While high-dose vaccines showed superior effectiveness in the 332,000-participant DANFLU-2 trial, the newly licensed mRNA-1010 vaccine showed higher rates of localized or systemic Grade 3 reactions.
Timeline
Studies included in the review were published between August 1, 2025, and June 30, 2026.
The mRNA-1010 vaccine received official licensure in the United States in August 2026.
The recommendations were prepared to inform the upcoming 2026-2027 respiratory season.
The Big Picture
This systematic review builds upon evidence established by the DANFLU-2 trial, reinforcing the efficacy of high-dose formulations in older populations. It marks a shift toward integrating diverse clinical trial data to refine immunization strategies for broader demographic segments.
Patients may see changes in vaccine options available at their local clinics, including high-dose and mRNA formulations. Consult with a healthcare provider to understand which vaccination type provides the most effective protection for your specific age group.
The takeaway
The data confirms that seasonal influenza vaccination remains a highly effective tool for preventing severe outcomes across all age groups. Individuals should prioritize staying up to date with the latest licensed vaccines to ensure maximum protection during the respiratory season.
Further reading
Learn more about respiratory health and disease management in our Asthma section.
Source note: This article includes information reported by Pharmacytimes.
Live Poll
Do you trust influenza vaccine recommendations issued without the guidance of federal advisory committees?
